SlideShare a Scribd company logo
2
Dr. Ashraf El Adawy 
Consultant Chest Physician 
TB TEAM EXPERT - WHO
TUBERCULOSIS... 
●The greatest killer of all time... 
●The captain of all the men of death... 
●Over the last century, TB has killed more than 100 million people.
TB was a death sentence for many
7 
One in four died of the disease in 1800, and by the late 1890's it was still one in seven. 
Until the early twentieth century it was the greatest killer of all.
Among the communicable disease, TB is the second leading cause of death world wide after HIV/ AIDS (cleveland clinic 2008) 
TB is one of the top 3 killer diseases world-wide along with HIV & malaria.
 “If the importance of a disease for mankind is measured by the number of fatalities it causes, then tuberculosis must be considered much more important than those most feared infectious diseases” 
9 
Robert Koch, March 24, 1882
Many names……0ne disease 
●Consumption 
●Phthisis 
●Pott's disease 
●White Plague are all terms used to refer to TB throughout history.
Earlier TB has been called by numerous names 
1.Consumption (because of the severe weight loss and the way the infection appeared to “consume” the patient), 
2.Phthisis pulmonaris 
3.White death (or white plague) because of the extreme pallor seen among those infected. 
11
TB has affected humans for millennia 
Tuberculosis has been known to mankind since ancient times. 
12
The depictions of a gibbus in statuettes of Ancient Egyptian and pre-Columbian origin represents clear evidence of spinal TB.
It describes a pulmonary consumption associated with the cervical lymph nodes. It recommended that it be treated with the surgical lancing of the cyst and the application of a ground mixture of acacia seyal, peas, fruits, animal blood, insect blood, honey and salt. 
The Ebers Papyrus, also known as Papyrus Ebers, is an Egyptian medical papyrus dating to circa 1550 BC. Among the oldest and most important medical papyri of ancient Egypt, it was purchased at Luxor, (Thebes) in the winter of 1873–74 by Georg Ebers. It is currently kept at the library of the University of Leipzig, in Germany 
The Ebers Papyrus
16
Akhenaten and his wife Nefertiti both died from tuberculosis 
17
460 BC 
Hippocrates identifies phtisis (greek word meaning "consumption") as the most widespread disease of the times and notes that is almost always fatal.
Aristotle (384–322 BC), believed phthisis to be contagious even though general opinion at the time tended to the alternative theory that the disease was hereditary.
Ebn Sina 
The Famous Arab Scientist (980-1037) 
in his book “Al-Kanoun” 
describedtuberculosis (Al-Sol) in details.
Although it was a prevalent killer, humans did not begin to notice and study this disease until Ibn Sina wrote “The Cannon of Medicine” in the 1020s 
Ibn Sina, was the first to note that pulmonary TB was a communicable disease thereby requiring a method of quarantine to limit its spread. 
21
Tuberculosis in the Middle ages 
Evidence of tuberculosis of the cervical lymph nodes or lymph nodes of the neck termed scrofula is found in the Middle ages. 
 It was termed as the “king’s evil” and was widely believed that the kings of England and France could cure scrofula simply by touching those affected 
22
Royal Touch 
Henry IV of France touching numerous sickly individuals during the ceremony of the "royal touch"
Mycobacterium tuberculosis (MTB) was the cause of the "White Plague" of the 17th and 18th centuries in Europe. 
 During this period nearly 25 percent of all adult deaths were caused by MTB 
24
The White Death: A History of Tuberculosis 
25
The scientific advances 
One of the most important physicians was René Laennec, (1781-1826). who died from the disease at the age of 45, after contracting tuberculosis while studying contagious patients and infected bodies. Laennec invented the stethoscope in 1816 
Rene Laennec 
(1781-1826)
27
In 1834 
In 1834, Johann Lukas Schönlein of Würzburg (1793–1864) coined the term ‘tuberculosis’ to describe affliction with tubercles.
Brehmer was diagnosed with tuberculosis and told to find a healthier climate. 
He went to the Himalayas, continued his studies, and found himself cured. 
 In 1854 he returned to Germany to study medicine, ultimately writing a dissertation titled "Tuberculosis is a Curable Disease".[ 
29 
1854 Hermann Brehmer
1854 Hermann Brehmer 
German Botanist 
Dissertation (TB is a curable disease) 
Established first sanatorium in Germany 
Beginning of sanatorium era
TB R/ in the pre-antibiotica era. 
Before the discovery of effective anti-tuberculosis drugs, (R/) of TB was mainly Conservative, directed at relief of symptoms, with attention to lifestyle 
Patients followed a regimen of bed rest, open air, and sunshine
1859 
Hermann Brehmer . Establishes the first sanatorium at Goerbersdorf in Silesia.
Typical set-up of the TB patients spontaneously 
recovered from TB (left: male ward; right: female 
ward) in the fresh mountain air at the Swiss Alpine 
Clinic (Heiligenschwendi, 1900)
34
35
36
Cases were treated at home, in sanatoria and / or in hospitals. Results of R/ were poor, only 25% of subjects with open TB had sputum conversion after 2- 6 months of sanatorium R/.. 
50% of all new smear positive cases died within 5 years, the other 50% survived with varying degrees of morbidity. 
37 
TB R/ in the pre-antibiotica era.
38 
Many referred to the disease as the “Romantic disease.“ Pulmonary TB was romanticized in the arts and music of the 19th century
Dumas's La Dame aux camélias 
39
Hugo's Les Misérables 
40
In 1882: Discovery of the causative agent 
On March 24, 1882, Dr. Robert Koch ,a German scientist announced the discovery of Mycobacterium tuberculosis, the bacteria that cause TB.
Robert Koch was awarded the Nobel Prize in medicine in 1905. 
In 1982, a century after Dr. Koch’s announcement, the first world TB day was sponsored by the WHO &IUATLD 
World TB Day is held on March 24 each year in commemoration of Koch’s discovery 
42
43
1895: X Ray 
Wilhelm Konrad von Roentgen 
Discovered the radiation that bears his name. With this discovery, it was now possible to follow and accurately review the progress and severity of a patient's disease.
1890 Robert Koch . Introduces tuberculin.
By Calmette and Guérin, 1906-1921 
Invention of BCG Vaccine
No New TB Vaccine in > 90 Years 
BCG developed in 1921
1944 onwards Start of the Chemotherapy era
1944 
Waksman, Schatz and Bugie . Discovered streptomycin, the first effective antibiotic against tuberculosis. 
Streptomycin purified from Streptomyces griseus was first administered to a human on November 20, 1944.
NOBEL PRIZE MEDICINE 1952 / SELMAN WAKSMAN 
50
History of anti-TB drugs 
1944 STREPTOMYCIN 
1949 P A S 
1952 ISONIAZID 
1954 PYRIZINAMIDE 
1955 CYCLOSERINE 
1962 ETHAMBUTOL 
1963 RIFAMPICIN
52 
Breakthrough in the Fight Against TB 
Drugs that could kill TB bacteria were discoveredin 1940s and 1950s 
Streptomycin (SM) discovered in 1943 
Isoniazid (INH) and p-aminosalicylic acid (PAS) discovered between 1943 and 1952
53
Sir John Crofton Leading figure in respiratory medicine and the treatment of tuberculosis 
1960 
Dr John Crofton, a TB expert, proposed that a combination of drugs — Streptomycin, PAS and Isoniazid — made TB completely curable and declared "all out war" to conquer the disease. 
54
1950 -1980 
Progressive decline in TB incidence in the industrialized countries 
1980s – 1990s 
The AIDS epidemic has serious repercussions on TB epidemiology, increasing the incidence of TB both in industrialized countries and in developing countries. 
Multi drug resistance poses increasing problems with regard to the efficacy of the therapy in use
Module 2 – Epidemiology of 
Tuberculosis 
10,000 
12,000 
14,000 
16,000 
18,000 
20,000 
22,000 
24,000 
26,000 
28,000 
1982 1986 1990 1994 1998 2002 2008 
20% increase 
No. of Cases 
Reported TB Cases, U.S., 1982-2008 
Year 
U.S. TB Resurgence 
1986 - 1992 
56
Module 1 – Transmission and Pathogenesis of Tuberculosis 
57 
TB Resurgence 
Increase in TB in mid 1980s 
Contributing factors: 
1.Inadequate funding for TB control programs 
2.HIV epidemic 
3.Increased immigration from countries where TB is common 
4.Spread in homeless shelters and correctional facilities 
5.Increase and spread of multidrug-resistant TB 
March 16, 1992 Newsweek Magazine Cover
58
The Global Emergency 
In 1993, The World Health Organization declares TB a global emergency, estimating that one third of the world's population (2 billion people) is latently infected with TB and 8-9 million cases of active TB occur each year. 
59
The Directly Observed Treatment Short-course (DOTS) Strategy was developed as a response to the global emergency 
Directly Observed Therapy Short Course (DOTS) strategy recommended by WHO and introduced to endemic countries. 
60
oDOTS is the internationally recommended strategy to control TB developed in 1995(WHO global strategy) . 
oDOTS has been described by the World Bank as “one of the most cost-effective of all health interventions.” 
oDOTS has been implemented in 184 countries.
Implementation of DOTS, 2006 
184 countries (out of 212) 
> 90%pop 
low incidence, non-DOTS 
10 - 90% pop 
No report 
non-DOTS 
Implementation of DOTS
TB Control: The 5 components of DOTS 
TB Register 
Political commitment 
Diagnosis by microscopy 
Adequate supply of SCC drugs 
Directly observed treatment 
Accountability
World Health Assembly 1991 
" The objectives of TB control as adopted by the (WHA)are to attain a global target of cure of 85% sputum-positive patients under treatment and detection of 70% of cases by the year 2000"
“The growing tuberculosis epidemic is no longer an emergency only for those who care about health, but for those who care about justice” 
(World Health Organization. TB - A global emergency. Geneva WHO 1994)
Global control of TB is a leading public health priority
The Global Targets 
We have clear and measurable targets to fight TB: 
Detection and cure through DOTS. 
70 
85 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
DETECTION TREATMENT SUCCESS 
DETECTION AND CURE TARGETS FOR 2005 in % 
DETECTION TREATMENT SUCCESS 
•Targets set for 2000; later postponed to 2005.
Status Of DOTS Implementation 
70 
32 
85 80 
0 
20 
40 
60 
80 
100 
Detection Target Detent ion Achieved Treatment success 
Target 
Treatment Success 
Achieved 
ACHIEVED vs. TARGET 
Limits to case detection under DOTS 
Detecting new cases is the main PROBLEM 
 
 
53 
83
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
1995 
1996 
1997 
1998 
1999 
2000 
2001 
2002 
2003 
2004 
2005 
•Case detection rate or cure rate (%) 
Target cure 85% 
Target detection 70% 
Case detection rate 2004: 53% Cure rate 2003: 83%
The final push to 70% case detection? 
0 
10 
20 
30 
40 
50 
60 
70 
80 
1990 1995 2000 2005 2010 2015 
Year 
Case detection DOTS, smear+ 
cases (%) 
average rate of 
progress 1995-2000 
accelerated progress 
to 2005 target 
WHO target 70% 
As DOTS coverage & cure rates are high, finding TB cases 
is now the priority area for TB control
A major obstacle in the fight to STOP TB is the rate of case detection. 
WE MUST ACCELERATE TB DETECTION RATES! 
DOTS is not the final solution to the TB crisis.
From DOTS to the Stop TB Strategy 
Building on Achievements for Future Planning 
Stop TB Partnership Symposium at the 37th UNION World Conference on TB and Lung Disease 
31st October 2006, Paris
Stop TB Strategy to reach the 2015 MDGs 
• Vision: A WORLD FREE OF TB • Goal:To dramatically reduce the global burden of TB by 2015 in line with the MDGs and the Stop TB Partnership targets
Global TB control targets 
2005: World Health Assembly: 
- To detect at least 70% of infectious TB cases 
- To treat successfully at least 85% of detected cases 
2015: 50% reduction in TB prevalence and death rates by 2015 2050 world free of TB 
2015: Goal 6: Combat HIV/AIDS, malaria and other 
diseases 
Target 8: to have halted by 2015 and begun to reverse 
the incidence… 
Indicator 23: prevalence and deaths associated with TB 
Indicator 24: proportion of TB cases detected 
and cured under DOTS
The Practical Approach to Lung health (PAL) is a syndromic approach to the management of patients who attend primary health care services for respiratory symptoms 
Patients over the age of 5 years attending primary health care (PHC) settings seek health care for respiratory symptoms.
The PAL strategy 
Rationale 
25-33% of patients go to PHC for respiratory diseases 
Primary care is weak and TB suspects are not identified 
Respiratory care should be standardized, co-ordinated, and cost-effective, as in DOTS and IMCI 
Solution 
Standardized syndromic guidelines for diagnosis and treatment 
Coordinated referral mechanisms between levels
PAL strategy 
Standardization of health care procedures 
Coordination between health care levels 
 Focus on priority respiratory diseases > 5 yrs: 
+ TB 
+ ARI (pneumonia) 
+ CRDs (asthma, COPD)
PAL helps detecting TB cases, among patients with respiratory symptoms within PHC settings and improves the quality of TB diagnoses through the appropriate management of patients with respiratory symptoms. 
PAL contributes to improving the quality of health care 
82
TB
84
The TB mortality rate has decreased 41% since 1990. 
No country has ever eliminated this disease. 
85
The World Health Organisation estimates that 20 million lives have been saved from TB in the past two decades as a result of global efforts to fight TB. This is good news, but there is still much to be done. Every day, 24,000 people fall ill with TB, and 3,836 people die - despite the fact that TB is curable. 
86
WHO Global TB Report, 2012 
8.7 million new cases of TB in 2011 1.4 million deaths in 2011 0.5 million MDR-TB cases TB is the biggest infectious killer among people infected with HIV TB is one of the top killers of women worldwide, half a million women died from TB in 2011.
89
Czech Rep. 
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO 2005. All rights reserved 
Ecuador 
Georgia 
Argentina 
Bangladesh 
Germany 
Rep of Korea 
Armenia 
Russian Fed. 
South Africa 
Portugal 
Latvia 
Mexico 
Peru 
USA 
Brazil 
UK 
Sweden 
Thailand 
Chile 
Based on information provided to WHO Stop TB Department - June 2008 
Spain 
China, Hong Kong SAR 
France 
Japan 
Norway 
Canada 
Italy 
Netherlands 
Estonia 
Lithuania 
Ireland 
Romania 
Israel 
Azerbaijan 
Poland 
Slovenia 
India 
Australia 
Mozambique 
Vietnam 
Countries with XDR-TB confirmed cases as of June 2008 
Ukraine 
Moldova 
Philippines 
Botswana 
Nepal 
Islamic Rep. of Iran 
Lesotho 
Swaziland 
Namibia
History of tb
History of tb
History of tb
History of tb

More Related Content

What's hot

NTEP (National Tuberculosis Elimination Programme).pptx
NTEP (National Tuberculosis Elimination Programme).pptxNTEP (National Tuberculosis Elimination Programme).pptx
NTEP (National Tuberculosis Elimination Programme).pptxImmanuel Joshua
 
End tb strategy
End tb strategyEnd tb strategy
End tb strategyrmch15cm
 
Pulmonary tb by dr waleed arshad
Pulmonary tb by dr waleed arshadPulmonary tb by dr waleed arshad
Pulmonary tb by dr waleed arshadWaleedArshad24
 
Tuberculosis slides
Tuberculosis slidesTuberculosis slides
Tuberculosis slidesnandicinta
 
Tuberculosis and diabetes mellitus double trouble
Tuberculosis and diabetes mellitus double troubleTuberculosis and diabetes mellitus double trouble
Tuberculosis and diabetes mellitus double troubleMEEQAT HOSPITAL
 
H I V/ T B CO INFECTION A CASE PRESENTATION
H I V/ T B  CO INFECTION A CASE PRESENTATIONH I V/ T B  CO INFECTION A CASE PRESENTATION
H I V/ T B CO INFECTION A CASE PRESENTATIONFarouq Dayyab
 
Revised Pediatric Tuberculosis guidelines (NTEP) 2020
Revised Pediatric Tuberculosis guidelines (NTEP) 2020Revised Pediatric Tuberculosis guidelines (NTEP) 2020
Revised Pediatric Tuberculosis guidelines (NTEP) 2020Sonali Paradhi Mhatre
 
HIV and TB coinfection
HIV and TB coinfectionHIV and TB coinfection
HIV and TB coinfectionswati2084
 
Bangladesh national guidelines and operational manual for tuberculosis dr sha...
Bangladesh national guidelines and operational manual for tuberculosis dr sha...Bangladesh national guidelines and operational manual for tuberculosis dr sha...
Bangladesh national guidelines and operational manual for tuberculosis dr sha...Bangabandhu Sheikh Mujib Medical University
 
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...Amol Patil
 
Epidemiology & prevention of tuberculosis
Epidemiology & prevention of tuberculosisEpidemiology & prevention of tuberculosis
Epidemiology & prevention of tuberculosisDr.Hemant Kumar
 
RNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended versionRNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended versionRxVichuZ
 

What's hot (20)

Infection control measures in tuberculosis Dr.T.V.Rao MD
Infection control measures in  tuberculosis Dr.T.V.Rao MDInfection control measures in  tuberculosis Dr.T.V.Rao MD
Infection control measures in tuberculosis Dr.T.V.Rao MD
 
Management of TB 2019
Management of TB 2019Management of TB 2019
Management of TB 2019
 
NTEP (National Tuberculosis Elimination Programme).pptx
NTEP (National Tuberculosis Elimination Programme).pptxNTEP (National Tuberculosis Elimination Programme).pptx
NTEP (National Tuberculosis Elimination Programme).pptx
 
EPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSISEPIDEMIOLOGY OF TUBERCULOSIS
EPIDEMIOLOGY OF TUBERCULOSIS
 
End tb strategy
End tb strategyEnd tb strategy
End tb strategy
 
Pulmonary tb by dr waleed arshad
Pulmonary tb by dr waleed arshadPulmonary tb by dr waleed arshad
Pulmonary tb by dr waleed arshad
 
Tuberculosis slides
Tuberculosis slidesTuberculosis slides
Tuberculosis slides
 
Tuberculosis and diabetes mellitus double trouble
Tuberculosis and diabetes mellitus double troubleTuberculosis and diabetes mellitus double trouble
Tuberculosis and diabetes mellitus double trouble
 
H I V/ T B CO INFECTION A CASE PRESENTATION
H I V/ T B  CO INFECTION A CASE PRESENTATIONH I V/ T B  CO INFECTION A CASE PRESENTATION
H I V/ T B CO INFECTION A CASE PRESENTATION
 
Sars lec
Sars lecSars lec
Sars lec
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Revised Pediatric Tuberculosis guidelines (NTEP) 2020
Revised Pediatric Tuberculosis guidelines (NTEP) 2020Revised Pediatric Tuberculosis guidelines (NTEP) 2020
Revised Pediatric Tuberculosis guidelines (NTEP) 2020
 
HIV and TB coinfection
HIV and TB coinfectionHIV and TB coinfection
HIV and TB coinfection
 
Bangladesh national guidelines and operational manual for tuberculosis dr sha...
Bangladesh national guidelines and operational manual for tuberculosis dr sha...Bangladesh national guidelines and operational manual for tuberculosis dr sha...
Bangladesh national guidelines and operational manual for tuberculosis dr sha...
 
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...
 
TB plus HIV
TB plus HIVTB plus HIV
TB plus HIV
 
Pulmonary tuberculosis..ptt
Pulmonary tuberculosis..pttPulmonary tuberculosis..ptt
Pulmonary tuberculosis..ptt
 
Epidemiology & prevention of tuberculosis
Epidemiology & prevention of tuberculosisEpidemiology & prevention of tuberculosis
Epidemiology & prevention of tuberculosis
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
RNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended versionRNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended version
 

Viewers also liked

Viewers also liked (20)

Pulmonary tuberculosis ppt
Pulmonary tuberculosis pptPulmonary tuberculosis ppt
Pulmonary tuberculosis ppt
 
Tuberculosis presentation
Tuberculosis presentationTuberculosis presentation
Tuberculosis presentation
 
Tuberculosis - World TB Day 2011
Tuberculosis - World TB Day 2011Tuberculosis - World TB Day 2011
Tuberculosis - World TB Day 2011
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
HIV
HIVHIV
HIV
 
Iberian medicine(colchis),georgian medical manuscripts.
Iberian medicine(colchis),georgian medical manuscripts.Iberian medicine(colchis),georgian medical manuscripts.
Iberian medicine(colchis),georgian medical manuscripts.
 
Tb
TbTb
Tb
 
Dr. nahla farahat immunophenotyping of multiple myeloma
Dr. nahla farahat   immunophenotyping of multiple myeloma Dr. nahla farahat   immunophenotyping of multiple myeloma
Dr. nahla farahat immunophenotyping of multiple myeloma
 
Dr. George Sundin - Antimicrobial Use in Plant Agriculture
Dr. George Sundin - Antimicrobial Use in Plant AgricultureDr. George Sundin - Antimicrobial Use in Plant Agriculture
Dr. George Sundin - Antimicrobial Use in Plant Agriculture
 
Managing Multiple Myeloma
Managing Multiple Myeloma Managing Multiple Myeloma
Managing Multiple Myeloma
 
Respiratory system quiz bowl
Respiratory system quiz bowlRespiratory system quiz bowl
Respiratory system quiz bowl
 
Biotech2012 spring 3_metabolomics
Biotech2012 spring 3_metabolomicsBiotech2012 spring 3_metabolomics
Biotech2012 spring 3_metabolomics
 
Newer drugs in multiple myeloma
Newer drugs in multiple myelomaNewer drugs in multiple myeloma
Newer drugs in multiple myeloma
 
RIQAS Calendar 2017
RIQAS Calendar 2017RIQAS Calendar 2017
RIQAS Calendar 2017
 
Tb
TbTb
Tb
 
Lymphadenopathy
LymphadenopathyLymphadenopathy
Lymphadenopathy
 
Soft tissue calcification of head and neck
Soft tissue calcification of head and neck Soft tissue calcification of head and neck
Soft tissue calcification of head and neck
 
Tuberculosis (extra pulmonary)
Tuberculosis (extra pulmonary)Tuberculosis (extra pulmonary)
Tuberculosis (extra pulmonary)
 
Miliary Tuberculosis (dr. mahesh)
Miliary Tuberculosis (dr. mahesh)Miliary Tuberculosis (dr. mahesh)
Miliary Tuberculosis (dr. mahesh)
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 

Similar to History of tb

Tuberculosis lecture 01 1 1
Tuberculosis lecture 01 1 1Tuberculosis lecture 01 1 1
Tuberculosis lecture 01 1 1Sky Storm
 
A review on coagulopathy in Covid-19 and its Homoeopathic management
A review on coagulopathy in Covid-19  and its  Homoeopathic management A review on coagulopathy in Covid-19  and its  Homoeopathic management
A review on coagulopathy in Covid-19 and its Homoeopathic management Dr DON J SCOTT BERIN G
 
C:\Documents And Settings\Jobrien\Desktop\O Brien\Tuberculosis For Lunch
C:\Documents And Settings\Jobrien\Desktop\O Brien\Tuberculosis For LunchC:\Documents And Settings\Jobrien\Desktop\O Brien\Tuberculosis For Lunch
C:\Documents And Settings\Jobrien\Desktop\O Brien\Tuberculosis For Lunchjameskobrien
 
Tuberculosis For Lunch
Tuberculosis For LunchTuberculosis For Lunch
Tuberculosis For Lunchjameskobrien
 
Infection in literature part 2 eng
Infection in literature part 2 engInfection in literature part 2 eng
Infection in literature part 2 engdrandreyst-p
 
Pulmonary Tuberculosis
Pulmonary Tuberculosis Pulmonary Tuberculosis
Pulmonary Tuberculosis Hamdi Turkey
 
Introduction with a few glances from history - opening words for the seminar_eng
Introduction with a few glances from history - opening words for the seminar_engIntroduction with a few glances from history - opening words for the seminar_eng
Introduction with a few glances from history - opening words for the seminar_engTHL
 
Clinical microbiology and molecular techniques
Clinical microbiology and molecular techniquesClinical microbiology and molecular techniques
Clinical microbiology and molecular techniquesIndhra Yogaesh
 
Flu shots and health
Flu shots and healthFlu shots and health
Flu shots and healthJohn Bergman
 
COVID-19 and Immunity The 21th Threat, By Prof. Mohamed Labib Salem, PhD
COVID-19 and Immunity The 21th Threat, By Prof. Mohamed Labib Salem, PhDCOVID-19 and Immunity The 21th Threat, By Prof. Mohamed Labib Salem, PhD
COVID-19 and Immunity The 21th Threat, By Prof. Mohamed Labib Salem, PhDProf. Mohamed Labib Salem
 
Robert Koch
Robert KochRobert Koch
Robert KochHappyMrH
 
What is medical coding and its use.docx
What is medical coding and its use.docxWhat is medical coding and its use.docx
What is medical coding and its use.docxwrite22
 
The largest pandemics throughout history and its consequences
The largest pandemics throughout history and its consequencesThe largest pandemics throughout history and its consequences
The largest pandemics throughout history and its consequencesFernando Alcoforado
 
Pulmonary tuberculosis
Pulmonary tuberculosisPulmonary tuberculosis
Pulmonary tuberculosisarun raj
 
Modelling Isoniazid Hepatotoxicity on HepG2 Cells By CYP2E1 Metabolism - Lond...
Modelling Isoniazid Hepatotoxicity on HepG2 Cells By CYP2E1 Metabolism - Lond...Modelling Isoniazid Hepatotoxicity on HepG2 Cells By CYP2E1 Metabolism - Lond...
Modelling Isoniazid Hepatotoxicity on HepG2 Cells By CYP2E1 Metabolism - Lond...Eric Garson
 
Epidemics & pandemics world & india- a case study- peterpdb
Epidemics & pandemics world & india- a case study- peterpdbEpidemics & pandemics world & india- a case study- peterpdb
Epidemics & pandemics world & india- a case study- peterpdbPeter Prasanta Debbarma
 
Tuberculosis: The Invisible Threat
Tuberculosis: The Invisible ThreatTuberculosis: The Invisible Threat
Tuberculosis: The Invisible Threatjayembee
 
History of Epidemics & Pandemics of World & India- A case study-peterpd
History of Epidemics & Pandemics of World & India- A case study-peterpdHistory of Epidemics & Pandemics of World & India- A case study-peterpd
History of Epidemics & Pandemics of World & India- A case study-peterpdPeter Prasanta Debbarma
 

Similar to History of tb (20)

Tuberculosis lecture 01 1 1
Tuberculosis lecture 01 1 1Tuberculosis lecture 01 1 1
Tuberculosis lecture 01 1 1
 
A review on coagulopathy in Covid-19 and its Homoeopathic management
A review on coagulopathy in Covid-19  and its  Homoeopathic management A review on coagulopathy in Covid-19  and its  Homoeopathic management
A review on coagulopathy in Covid-19 and its Homoeopathic management
 
728 1993-2-pb
728 1993-2-pb728 1993-2-pb
728 1993-2-pb
 
C:\Documents And Settings\Jobrien\Desktop\O Brien\Tuberculosis For Lunch
C:\Documents And Settings\Jobrien\Desktop\O Brien\Tuberculosis For LunchC:\Documents And Settings\Jobrien\Desktop\O Brien\Tuberculosis For Lunch
C:\Documents And Settings\Jobrien\Desktop\O Brien\Tuberculosis For Lunch
 
Tuberculosis For Lunch
Tuberculosis For LunchTuberculosis For Lunch
Tuberculosis For Lunch
 
Infection in literature part 2 eng
Infection in literature part 2 engInfection in literature part 2 eng
Infection in literature part 2 eng
 
Pulmonary Tuberculosis
Pulmonary Tuberculosis Pulmonary Tuberculosis
Pulmonary Tuberculosis
 
Introduction with a few glances from history - opening words for the seminar_eng
Introduction with a few glances from history - opening words for the seminar_engIntroduction with a few glances from history - opening words for the seminar_eng
Introduction with a few glances from history - opening words for the seminar_eng
 
Clinical microbiology and molecular techniques
Clinical microbiology and molecular techniquesClinical microbiology and molecular techniques
Clinical microbiology and molecular techniques
 
Flu shots and health
Flu shots and healthFlu shots and health
Flu shots and health
 
COVID-19 and Immunity The 21th Threat, By Prof. Mohamed Labib Salem, PhD
COVID-19 and Immunity The 21th Threat, By Prof. Mohamed Labib Salem, PhDCOVID-19 and Immunity The 21th Threat, By Prof. Mohamed Labib Salem, PhD
COVID-19 and Immunity The 21th Threat, By Prof. Mohamed Labib Salem, PhD
 
Robert Koch
Robert KochRobert Koch
Robert Koch
 
What is medical coding and its use.docx
What is medical coding and its use.docxWhat is medical coding and its use.docx
What is medical coding and its use.docx
 
Plague: The Black Death.pptx
Plague: The Black Death.pptxPlague: The Black Death.pptx
Plague: The Black Death.pptx
 
The largest pandemics throughout history and its consequences
The largest pandemics throughout history and its consequencesThe largest pandemics throughout history and its consequences
The largest pandemics throughout history and its consequences
 
Pulmonary tuberculosis
Pulmonary tuberculosisPulmonary tuberculosis
Pulmonary tuberculosis
 
Modelling Isoniazid Hepatotoxicity on HepG2 Cells By CYP2E1 Metabolism - Lond...
Modelling Isoniazid Hepatotoxicity on HepG2 Cells By CYP2E1 Metabolism - Lond...Modelling Isoniazid Hepatotoxicity on HepG2 Cells By CYP2E1 Metabolism - Lond...
Modelling Isoniazid Hepatotoxicity on HepG2 Cells By CYP2E1 Metabolism - Lond...
 
Epidemics & pandemics world & india- a case study- peterpdb
Epidemics & pandemics world & india- a case study- peterpdbEpidemics & pandemics world & india- a case study- peterpdb
Epidemics & pandemics world & india- a case study- peterpdb
 
Tuberculosis: The Invisible Threat
Tuberculosis: The Invisible ThreatTuberculosis: The Invisible Threat
Tuberculosis: The Invisible Threat
 
History of Epidemics & Pandemics of World & India- A case study-peterpd
History of Epidemics & Pandemics of World & India- A case study-peterpdHistory of Epidemics & Pandemics of World & India- A case study-peterpd
History of Epidemics & Pandemics of World & India- A case study-peterpd
 

More from Ashraf ElAdawy

How to get your taste and smell back after covid-19?
How to get your taste and smell back after covid-19?How to get your taste and smell back after covid-19?
How to get your taste and smell back after covid-19?Ashraf ElAdawy
 
Quadrivalent influenza vaccine
Quadrivalent influenza vaccineQuadrivalent influenza vaccine
Quadrivalent influenza vaccineAshraf ElAdawy
 
Brain fog, insomnia, and stress: Coping after COVID
Brain fog, insomnia, and stress: Coping after COVIDBrain fog, insomnia, and stress: Coping after COVID
Brain fog, insomnia, and stress: Coping after COVIDAshraf ElAdawy
 
How to manage fatigue after covid-19
How to manage fatigue after covid-19How to manage fatigue after covid-19
How to manage fatigue after covid-19Ashraf ElAdawy
 
Managing breathlessness with long covid
Managing breathlessness with long covidManaging breathlessness with long covid
Managing breathlessness with long covidAshraf ElAdawy
 
COVID-19 &Tuberculosis What is The Link?
COVID-19 &Tuberculosis  What is The Link?COVID-19 &Tuberculosis  What is The Link?
COVID-19 &Tuberculosis What is The Link?Ashraf ElAdawy
 
COVID-19 : A look at possible future Scenarios?
COVID-19 : A look at possible future Scenarios?  COVID-19 : A look at possible future Scenarios?
COVID-19 : A look at possible future Scenarios? Ashraf ElAdawy
 
Asthma, COPD with COVID-19: What should HCPs need to know?
Asthma, COPD with COVID-19: What should HCPs need to know?Asthma, COPD with COVID-19: What should HCPs need to know?
Asthma, COPD with COVID-19: What should HCPs need to know?Ashraf ElAdawy
 
Novel coronavirus (COVID-2019) What we need to know?
Novel coronavirus (COVID-2019) What we need to know?Novel coronavirus (COVID-2019) What we need to know?
Novel coronavirus (COVID-2019) What we need to know?Ashraf ElAdawy
 
فيروس الكورونا المستجد 2019
فيروس الكورونا المستجد 2019فيروس الكورونا المستجد 2019
فيروس الكورونا المستجد 2019Ashraf ElAdawy
 
Novel corona virus 2019 (2019 - nCov)
Novel corona virus 2019 (2019 - nCov) Novel corona virus 2019 (2019 - nCov)
Novel corona virus 2019 (2019 - nCov) Ashraf ElAdawy
 
Asthma Inhaler Techniques In Children
 Asthma Inhaler Techniques In Children Asthma Inhaler Techniques In Children
Asthma Inhaler Techniques In ChildrenAshraf ElAdawy
 
Asthma Medications in Clinical Practice - Part 2
Asthma Medications in Clinical Practice - Part 2Asthma Medications in Clinical Practice - Part 2
Asthma Medications in Clinical Practice - Part 2Ashraf ElAdawy
 
Asthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New ApproachAsthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New ApproachAshraf ElAdawy
 
Updates on pharmacological management of COPD 2020
Updates on pharmacological management of COPD 2020Updates on pharmacological management of COPD 2020
Updates on pharmacological management of COPD 2020Ashraf ElAdawy
 
Asthma Medications in Clinical Practice - Part 1
Asthma Medications in Clinical Practice - Part 1Asthma Medications in Clinical Practice - Part 1
Asthma Medications in Clinical Practice - Part 1Ashraf ElAdawy
 
Asthma and inhaler usage tips - part 2
Asthma and inhaler usage tips - part 2Asthma and inhaler usage tips - part 2
Asthma and inhaler usage tips - part 2Ashraf ElAdawy
 
Pneumococcal vaccine in adults “Clinical Scenarios”
Pneumococcal vaccine in adults “Clinical Scenarios”Pneumococcal vaccine in adults “Clinical Scenarios”
Pneumococcal vaccine in adults “Clinical Scenarios”Ashraf ElAdawy
 
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”Ashraf ElAdawy
 

More from Ashraf ElAdawy (20)

How to get your taste and smell back after covid-19?
How to get your taste and smell back after covid-19?How to get your taste and smell back after covid-19?
How to get your taste and smell back after covid-19?
 
Quadrivalent influenza vaccine
Quadrivalent influenza vaccineQuadrivalent influenza vaccine
Quadrivalent influenza vaccine
 
Brain fog, insomnia, and stress: Coping after COVID
Brain fog, insomnia, and stress: Coping after COVIDBrain fog, insomnia, and stress: Coping after COVID
Brain fog, insomnia, and stress: Coping after COVID
 
How to manage fatigue after covid-19
How to manage fatigue after covid-19How to manage fatigue after covid-19
How to manage fatigue after covid-19
 
Managing breathlessness with long covid
Managing breathlessness with long covidManaging breathlessness with long covid
Managing breathlessness with long covid
 
Post COVID Syndrome
Post COVID SyndromePost COVID Syndrome
Post COVID Syndrome
 
COVID-19 &Tuberculosis What is The Link?
COVID-19 &Tuberculosis  What is The Link?COVID-19 &Tuberculosis  What is The Link?
COVID-19 &Tuberculosis What is The Link?
 
COVID-19 : A look at possible future Scenarios?
COVID-19 : A look at possible future Scenarios?  COVID-19 : A look at possible future Scenarios?
COVID-19 : A look at possible future Scenarios?
 
Asthma, COPD with COVID-19: What should HCPs need to know?
Asthma, COPD with COVID-19: What should HCPs need to know?Asthma, COPD with COVID-19: What should HCPs need to know?
Asthma, COPD with COVID-19: What should HCPs need to know?
 
Novel coronavirus (COVID-2019) What we need to know?
Novel coronavirus (COVID-2019) What we need to know?Novel coronavirus (COVID-2019) What we need to know?
Novel coronavirus (COVID-2019) What we need to know?
 
فيروس الكورونا المستجد 2019
فيروس الكورونا المستجد 2019فيروس الكورونا المستجد 2019
فيروس الكورونا المستجد 2019
 
Novel corona virus 2019 (2019 - nCov)
Novel corona virus 2019 (2019 - nCov) Novel corona virus 2019 (2019 - nCov)
Novel corona virus 2019 (2019 - nCov)
 
Asthma Inhaler Techniques In Children
 Asthma Inhaler Techniques In Children Asthma Inhaler Techniques In Children
Asthma Inhaler Techniques In Children
 
Asthma Medications in Clinical Practice - Part 2
Asthma Medications in Clinical Practice - Part 2Asthma Medications in Clinical Practice - Part 2
Asthma Medications in Clinical Practice - Part 2
 
Asthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New ApproachAsthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New Approach
 
Updates on pharmacological management of COPD 2020
Updates on pharmacological management of COPD 2020Updates on pharmacological management of COPD 2020
Updates on pharmacological management of COPD 2020
 
Asthma Medications in Clinical Practice - Part 1
Asthma Medications in Clinical Practice - Part 1Asthma Medications in Clinical Practice - Part 1
Asthma Medications in Clinical Practice - Part 1
 
Asthma and inhaler usage tips - part 2
Asthma and inhaler usage tips - part 2Asthma and inhaler usage tips - part 2
Asthma and inhaler usage tips - part 2
 
Pneumococcal vaccine in adults “Clinical Scenarios”
Pneumococcal vaccine in adults “Clinical Scenarios”Pneumococcal vaccine in adults “Clinical Scenarios”
Pneumococcal vaccine in adults “Clinical Scenarios”
 
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
Pneumococcal vaccine in adults with CKD “Clinical Scenarios”
 

Recently uploaded

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1DR SETH JOTHAM
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxdrwaque
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Catherine Liao
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...Catherine Liao
 
Fundamental of Radiobiology -SABBU.pptx
Fundamental of Radiobiology  -SABBU.pptxFundamental of Radiobiology  -SABBU.pptx
Fundamental of Radiobiology -SABBU.pptxSabbu Khatoon
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentabdeli bhadarva
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Catherine Liao
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxDr KHALID B.M
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfDr Jeenal Mistry
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMeenakshiGursamy
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyDr KHALID B.M
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxgauripg8
 
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Catherine Liao
 
Blue Printing in medical education by Dr.Mumtaz Ali.pptx
Blue Printing in medical education by Dr.Mumtaz Ali.pptxBlue Printing in medical education by Dr.Mumtaz Ali.pptx
Blue Printing in medical education by Dr.Mumtaz Ali.pptxNeurosurgeon Mumtaz Ali Narejo
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsShweta
 
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t..."Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...Catherine Liao
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
5cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +852975043415cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +85297504341Sherrylee83
 

Recently uploaded (20)

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Fundamental of Radiobiology -SABBU.pptx
Fundamental of Radiobiology  -SABBU.pptxFundamental of Radiobiology  -SABBU.pptx
Fundamental of Radiobiology -SABBU.pptx
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal TestimonyAptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
 
Blue Printing in medical education by Dr.Mumtaz Ali.pptx
Blue Printing in medical education by Dr.Mumtaz Ali.pptxBlue Printing in medical education by Dr.Mumtaz Ali.pptx
Blue Printing in medical education by Dr.Mumtaz Ali.pptx
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t..."Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
 
Contact dermaititis (irritant and allergic).pdf
Contact dermaititis (irritant and allergic).pdfContact dermaititis (irritant and allergic).pdf
Contact dermaititis (irritant and allergic).pdf
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
5cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +852975043415cl adbb 5cladba cheap and fine Telegram: +85297504341
5cl adbb 5cladba cheap and fine Telegram: +85297504341
 

History of tb

  • 1.
  • 2. 2
  • 3. Dr. Ashraf El Adawy Consultant Chest Physician TB TEAM EXPERT - WHO
  • 4. TUBERCULOSIS... ●The greatest killer of all time... ●The captain of all the men of death... ●Over the last century, TB has killed more than 100 million people.
  • 5. TB was a death sentence for many
  • 6.
  • 7. 7 One in four died of the disease in 1800, and by the late 1890's it was still one in seven. Until the early twentieth century it was the greatest killer of all.
  • 8. Among the communicable disease, TB is the second leading cause of death world wide after HIV/ AIDS (cleveland clinic 2008) TB is one of the top 3 killer diseases world-wide along with HIV & malaria.
  • 9.  “If the importance of a disease for mankind is measured by the number of fatalities it causes, then tuberculosis must be considered much more important than those most feared infectious diseases” 9 Robert Koch, March 24, 1882
  • 10. Many names……0ne disease ●Consumption ●Phthisis ●Pott's disease ●White Plague are all terms used to refer to TB throughout history.
  • 11. Earlier TB has been called by numerous names 1.Consumption (because of the severe weight loss and the way the infection appeared to “consume” the patient), 2.Phthisis pulmonaris 3.White death (or white plague) because of the extreme pallor seen among those infected. 11
  • 12. TB has affected humans for millennia Tuberculosis has been known to mankind since ancient times. 12
  • 13.
  • 14. The depictions of a gibbus in statuettes of Ancient Egyptian and pre-Columbian origin represents clear evidence of spinal TB.
  • 15. It describes a pulmonary consumption associated with the cervical lymph nodes. It recommended that it be treated with the surgical lancing of the cyst and the application of a ground mixture of acacia seyal, peas, fruits, animal blood, insect blood, honey and salt. The Ebers Papyrus, also known as Papyrus Ebers, is an Egyptian medical papyrus dating to circa 1550 BC. Among the oldest and most important medical papyri of ancient Egypt, it was purchased at Luxor, (Thebes) in the winter of 1873–74 by Georg Ebers. It is currently kept at the library of the University of Leipzig, in Germany The Ebers Papyrus
  • 16. 16
  • 17. Akhenaten and his wife Nefertiti both died from tuberculosis 17
  • 18. 460 BC Hippocrates identifies phtisis (greek word meaning "consumption") as the most widespread disease of the times and notes that is almost always fatal.
  • 19. Aristotle (384–322 BC), believed phthisis to be contagious even though general opinion at the time tended to the alternative theory that the disease was hereditary.
  • 20. Ebn Sina The Famous Arab Scientist (980-1037) in his book “Al-Kanoun” describedtuberculosis (Al-Sol) in details.
  • 21. Although it was a prevalent killer, humans did not begin to notice and study this disease until Ibn Sina wrote “The Cannon of Medicine” in the 1020s Ibn Sina, was the first to note that pulmonary TB was a communicable disease thereby requiring a method of quarantine to limit its spread. 21
  • 22. Tuberculosis in the Middle ages Evidence of tuberculosis of the cervical lymph nodes or lymph nodes of the neck termed scrofula is found in the Middle ages.  It was termed as the “king’s evil” and was widely believed that the kings of England and France could cure scrofula simply by touching those affected 22
  • 23. Royal Touch Henry IV of France touching numerous sickly individuals during the ceremony of the "royal touch"
  • 24. Mycobacterium tuberculosis (MTB) was the cause of the "White Plague" of the 17th and 18th centuries in Europe.  During this period nearly 25 percent of all adult deaths were caused by MTB 24
  • 25. The White Death: A History of Tuberculosis 25
  • 26. The scientific advances One of the most important physicians was René Laennec, (1781-1826). who died from the disease at the age of 45, after contracting tuberculosis while studying contagious patients and infected bodies. Laennec invented the stethoscope in 1816 Rene Laennec (1781-1826)
  • 27. 27
  • 28. In 1834 In 1834, Johann Lukas Schönlein of Würzburg (1793–1864) coined the term ‘tuberculosis’ to describe affliction with tubercles.
  • 29. Brehmer was diagnosed with tuberculosis and told to find a healthier climate. He went to the Himalayas, continued his studies, and found himself cured.  In 1854 he returned to Germany to study medicine, ultimately writing a dissertation titled "Tuberculosis is a Curable Disease".[ 29 1854 Hermann Brehmer
  • 30. 1854 Hermann Brehmer German Botanist Dissertation (TB is a curable disease) Established first sanatorium in Germany Beginning of sanatorium era
  • 31. TB R/ in the pre-antibiotica era. Before the discovery of effective anti-tuberculosis drugs, (R/) of TB was mainly Conservative, directed at relief of symptoms, with attention to lifestyle Patients followed a regimen of bed rest, open air, and sunshine
  • 32. 1859 Hermann Brehmer . Establishes the first sanatorium at Goerbersdorf in Silesia.
  • 33. Typical set-up of the TB patients spontaneously recovered from TB (left: male ward; right: female ward) in the fresh mountain air at the Swiss Alpine Clinic (Heiligenschwendi, 1900)
  • 34. 34
  • 35. 35
  • 36. 36
  • 37. Cases were treated at home, in sanatoria and / or in hospitals. Results of R/ were poor, only 25% of subjects with open TB had sputum conversion after 2- 6 months of sanatorium R/.. 50% of all new smear positive cases died within 5 years, the other 50% survived with varying degrees of morbidity. 37 TB R/ in the pre-antibiotica era.
  • 38. 38 Many referred to the disease as the “Romantic disease.“ Pulmonary TB was romanticized in the arts and music of the 19th century
  • 39. Dumas's La Dame aux camélias 39
  • 41. In 1882: Discovery of the causative agent On March 24, 1882, Dr. Robert Koch ,a German scientist announced the discovery of Mycobacterium tuberculosis, the bacteria that cause TB.
  • 42. Robert Koch was awarded the Nobel Prize in medicine in 1905. In 1982, a century after Dr. Koch’s announcement, the first world TB day was sponsored by the WHO &IUATLD World TB Day is held on March 24 each year in commemoration of Koch’s discovery 42
  • 43. 43
  • 44. 1895: X Ray Wilhelm Konrad von Roentgen Discovered the radiation that bears his name. With this discovery, it was now possible to follow and accurately review the progress and severity of a patient's disease.
  • 45. 1890 Robert Koch . Introduces tuberculin.
  • 46. By Calmette and Guérin, 1906-1921 Invention of BCG Vaccine
  • 47. No New TB Vaccine in > 90 Years BCG developed in 1921
  • 48. 1944 onwards Start of the Chemotherapy era
  • 49. 1944 Waksman, Schatz and Bugie . Discovered streptomycin, the first effective antibiotic against tuberculosis. Streptomycin purified from Streptomyces griseus was first administered to a human on November 20, 1944.
  • 50. NOBEL PRIZE MEDICINE 1952 / SELMAN WAKSMAN 50
  • 51. History of anti-TB drugs 1944 STREPTOMYCIN 1949 P A S 1952 ISONIAZID 1954 PYRIZINAMIDE 1955 CYCLOSERINE 1962 ETHAMBUTOL 1963 RIFAMPICIN
  • 52. 52 Breakthrough in the Fight Against TB Drugs that could kill TB bacteria were discoveredin 1940s and 1950s Streptomycin (SM) discovered in 1943 Isoniazid (INH) and p-aminosalicylic acid (PAS) discovered between 1943 and 1952
  • 53. 53
  • 54. Sir John Crofton Leading figure in respiratory medicine and the treatment of tuberculosis 1960 Dr John Crofton, a TB expert, proposed that a combination of drugs — Streptomycin, PAS and Isoniazid — made TB completely curable and declared "all out war" to conquer the disease. 54
  • 55. 1950 -1980 Progressive decline in TB incidence in the industrialized countries 1980s – 1990s The AIDS epidemic has serious repercussions on TB epidemiology, increasing the incidence of TB both in industrialized countries and in developing countries. Multi drug resistance poses increasing problems with regard to the efficacy of the therapy in use
  • 56. Module 2 – Epidemiology of Tuberculosis 10,000 12,000 14,000 16,000 18,000 20,000 22,000 24,000 26,000 28,000 1982 1986 1990 1994 1998 2002 2008 20% increase No. of Cases Reported TB Cases, U.S., 1982-2008 Year U.S. TB Resurgence 1986 - 1992 56
  • 57. Module 1 – Transmission and Pathogenesis of Tuberculosis 57 TB Resurgence Increase in TB in mid 1980s Contributing factors: 1.Inadequate funding for TB control programs 2.HIV epidemic 3.Increased immigration from countries where TB is common 4.Spread in homeless shelters and correctional facilities 5.Increase and spread of multidrug-resistant TB March 16, 1992 Newsweek Magazine Cover
  • 58. 58
  • 59. The Global Emergency In 1993, The World Health Organization declares TB a global emergency, estimating that one third of the world's population (2 billion people) is latently infected with TB and 8-9 million cases of active TB occur each year. 59
  • 60. The Directly Observed Treatment Short-course (DOTS) Strategy was developed as a response to the global emergency Directly Observed Therapy Short Course (DOTS) strategy recommended by WHO and introduced to endemic countries. 60
  • 61. oDOTS is the internationally recommended strategy to control TB developed in 1995(WHO global strategy) . oDOTS has been described by the World Bank as “one of the most cost-effective of all health interventions.” oDOTS has been implemented in 184 countries.
  • 62. Implementation of DOTS, 2006 184 countries (out of 212) > 90%pop low incidence, non-DOTS 10 - 90% pop No report non-DOTS Implementation of DOTS
  • 63. TB Control: The 5 components of DOTS TB Register Political commitment Diagnosis by microscopy Adequate supply of SCC drugs Directly observed treatment Accountability
  • 64. World Health Assembly 1991 " The objectives of TB control as adopted by the (WHA)are to attain a global target of cure of 85% sputum-positive patients under treatment and detection of 70% of cases by the year 2000"
  • 65. “The growing tuberculosis epidemic is no longer an emergency only for those who care about health, but for those who care about justice” (World Health Organization. TB - A global emergency. Geneva WHO 1994)
  • 66.
  • 67. Global control of TB is a leading public health priority
  • 68. The Global Targets We have clear and measurable targets to fight TB: Detection and cure through DOTS. 70 85 0 10 20 30 40 50 60 70 80 90 100 DETECTION TREATMENT SUCCESS DETECTION AND CURE TARGETS FOR 2005 in % DETECTION TREATMENT SUCCESS •Targets set for 2000; later postponed to 2005.
  • 69. Status Of DOTS Implementation 70 32 85 80 0 20 40 60 80 100 Detection Target Detent ion Achieved Treatment success Target Treatment Success Achieved ACHIEVED vs. TARGET Limits to case detection under DOTS Detecting new cases is the main PROBLEM   53 83
  • 70. 0 10 20 30 40 50 60 70 80 90 100 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 •Case detection rate or cure rate (%) Target cure 85% Target detection 70% Case detection rate 2004: 53% Cure rate 2003: 83%
  • 71.
  • 72. The final push to 70% case detection? 0 10 20 30 40 50 60 70 80 1990 1995 2000 2005 2010 2015 Year Case detection DOTS, smear+ cases (%) average rate of progress 1995-2000 accelerated progress to 2005 target WHO target 70% As DOTS coverage & cure rates are high, finding TB cases is now the priority area for TB control
  • 73. A major obstacle in the fight to STOP TB is the rate of case detection. WE MUST ACCELERATE TB DETECTION RATES! DOTS is not the final solution to the TB crisis.
  • 74. From DOTS to the Stop TB Strategy Building on Achievements for Future Planning Stop TB Partnership Symposium at the 37th UNION World Conference on TB and Lung Disease 31st October 2006, Paris
  • 75. Stop TB Strategy to reach the 2015 MDGs • Vision: A WORLD FREE OF TB • Goal:To dramatically reduce the global burden of TB by 2015 in line with the MDGs and the Stop TB Partnership targets
  • 76. Global TB control targets 2005: World Health Assembly: - To detect at least 70% of infectious TB cases - To treat successfully at least 85% of detected cases 2015: 50% reduction in TB prevalence and death rates by 2015 2050 world free of TB 2015: Goal 6: Combat HIV/AIDS, malaria and other diseases Target 8: to have halted by 2015 and begun to reverse the incidence… Indicator 23: prevalence and deaths associated with TB Indicator 24: proportion of TB cases detected and cured under DOTS
  • 77.
  • 78.
  • 79. The Practical Approach to Lung health (PAL) is a syndromic approach to the management of patients who attend primary health care services for respiratory symptoms Patients over the age of 5 years attending primary health care (PHC) settings seek health care for respiratory symptoms.
  • 80. The PAL strategy Rationale 25-33% of patients go to PHC for respiratory diseases Primary care is weak and TB suspects are not identified Respiratory care should be standardized, co-ordinated, and cost-effective, as in DOTS and IMCI Solution Standardized syndromic guidelines for diagnosis and treatment Coordinated referral mechanisms between levels
  • 81. PAL strategy Standardization of health care procedures Coordination between health care levels  Focus on priority respiratory diseases > 5 yrs: + TB + ARI (pneumonia) + CRDs (asthma, COPD)
  • 82. PAL helps detecting TB cases, among patients with respiratory symptoms within PHC settings and improves the quality of TB diagnoses through the appropriate management of patients with respiratory symptoms. PAL contributes to improving the quality of health care 82
  • 83. TB
  • 84. 84
  • 85. The TB mortality rate has decreased 41% since 1990. No country has ever eliminated this disease. 85
  • 86. The World Health Organisation estimates that 20 million lives have been saved from TB in the past two decades as a result of global efforts to fight TB. This is good news, but there is still much to be done. Every day, 24,000 people fall ill with TB, and 3,836 people die - despite the fact that TB is curable. 86
  • 87.
  • 88. WHO Global TB Report, 2012 8.7 million new cases of TB in 2011 1.4 million deaths in 2011 0.5 million MDR-TB cases TB is the biggest infectious killer among people infected with HIV TB is one of the top killers of women worldwide, half a million women died from TB in 2011.
  • 89. 89
  • 90.
  • 91. Czech Rep. The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO 2005. All rights reserved Ecuador Georgia Argentina Bangladesh Germany Rep of Korea Armenia Russian Fed. South Africa Portugal Latvia Mexico Peru USA Brazil UK Sweden Thailand Chile Based on information provided to WHO Stop TB Department - June 2008 Spain China, Hong Kong SAR France Japan Norway Canada Italy Netherlands Estonia Lithuania Ireland Romania Israel Azerbaijan Poland Slovenia India Australia Mozambique Vietnam Countries with XDR-TB confirmed cases as of June 2008 Ukraine Moldova Philippines Botswana Nepal Islamic Rep. of Iran Lesotho Swaziland Namibia